Novartis Annual Results

Annual Results 2017 - Jan 24, 2018

Media release

English (PDF 0.4 MB)

Deutsch (PDF 0.3 MB)

Français (PDF 0.5 MB)

Condensed financial report (PDF 0.5 MB)

Webcast and presentations

Media

Watch the webcast

Download the presentation (PDF 10 MB)

Investors

Watch the webcast

Download the presentation (PDF 2.8 MB)

Download the podcast (MP3 40 MB)

---

Annual Report 2017

Our Annual Report provides an overview of our strategy and reviews the performance of Novartis in 2017.

Download the full 2017 Annual Report:
High resolution (PDF 8.4 MB)
Low resolution (PDF 5.0 MB)

To request a hard copy, fill out the order form.

Visit the Annual Report 2017 section

View archived presentations and webcasts from past events

 

---

Form 20-F 2017

Documents Novartis results in line with requirements of the US Securities and Exchange Commission (SEC).

English (PDF 4.2 MB)

---

XBRL package

Documents Novartis results in XML format in line with requirements of the US Securities and Exchange Commission (SEC).

XBRL Package (ZIP 0.6 MB)

Annual Results 2016 - Jan 25, 2017

 

Continuing operations2
Key figures1	FY 2016 (USD m)	FY 2015 (USD m)	% change (USD/cc)
Net sales	48,518	49,414	-2 (cc: 0)
Operating income	8,268	8,977	-8 (cc: -3)
Net income	6,698	7,028	-5 (cc: 1)
EPS (USD)	2.82	2.92	-3 (cc: 2)
Free cash flow	9,455	9,259	2
Core
Operating income	12,987	13,790	-6 (cc: -2)
Net income	11,314	12,041	-6 (cc: -3)
EPS (USD)	4.75	5.01	-5 (cc: -2)

 

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 50 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
2. Refers to continuing operations, defined on page 41 of the Condensed Financial Report.

 

Media release

English (PDF 0.4 MB)

Deutsch (PDF 0.4 MB)

Français (PDF 0.4 MB)

 

Condensed financial report (PDF 0.5 MB)

Download the podcast (MP3 100 MB)

Download the presentations:
Q4 and Full Year 2016 Results (PDF 2.7 MB)
Development Update (PDF 2.5 MB)
Research Update (PDF 2.4 MB)

Annual Results 2014 - Jan 27, 2015

 

		excl. Diagnostics[1]		Reported
	FY 2014[2] (USD m)	FY 2013 (USD m)	% change (USD/cc[1])	FY 2013 (USD m)
Net sales	57,996	57,355	1 (cc: 3)	57,920
Operating income	10,736	10,671	1 (cc: 7)	10,910
Net income	10,280	9,144	12 (cc: 19)	9,292
EPS (USD)	4.21	3.70	14 (cc: 20)	3.76
Free cash flow	10,762	9,592	12	9,945
Core1
Operating income	14,616	14,191	3 (cc: 8)
Net income	12,755	12,351	3 (cc: 8)
EPS (USD)	5.23	5.01	4 (cc: 10)

 

 

1. Constant currencies (cc), core results, free cash flow and 2013 data excluding the blood transfusion diagnostics unit are non-IFRS measures. An explanation of non-IFRS measures can be found on page 54 of the Condensed Financial Report (CFR).
2. 2014 results exclude depreciation and amortization related to discontinuing operations from the portfolio transformation announcement date. See page 22 of the CFR.

 

Media release

English (PDF 0.5 MB)

Deutsch (PDF 0.5 MB)

Français (PDF 0.8 MB)

Condensed financial report (PDF 0.6 MB)